Eric J. Sherman, MD, Head and Neck Oncology Service, Memorial Sloan-Kettering Cancer Center, discusses a pilot study of selumetinib-enhanced radioiodine uptake in advanced thyroid cancer.

This study was conducted to determine whether selumetinib could reverse refractoriness to radioiodine in patients with metastatic thyroid cancer. An  iodine-124 positron-emission tomography (I-124 PET scan) was performed before and after selumetinib administration (75 mg twice daily). Sherman says that an I-124 PET scan is an adequate way of measuring change objectively in each lesion.

In the study, 12 patients had an increase in radioactive iodine in their tumors. Eight (of the 12) patients had a significant enough uptake to be treated with radioactive iodine. Sherman believes the data from this pilot study could benefit patients with early disease.

OncLive TV

® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers. 

Head & Neck Cancers

The OncLive Head and Neck Cancer condition center page is a comprehensive resource for clinical news and expert insights on treatment for patients with head and neck cancer. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research within head and neck cancer. 

Dr. Sherman on Selumetinib-Enhanced Radioiodine Uptake